NYSE:PRGO Perrigo Q3 2026 Earnings Results & Report $15.95 -0.09 (-0.57%) Closing price 11/20/2026 03:59 PM EasternExtended Trading$15.94 0.00 (-0.02%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Perrigo beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 4, 2026. The company reported EPS of $0.60 versus the $0.5110 consensus estimate, while revenue of $988.60 million topped the $984.80 million estimate by $3.80 million. Revenue decreased 5.2% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 4, 2026TimeBefore Market OpensConference Call8:30 AM ET Perrigo EPS ResultsActual EPS$0.60Consensus EPS $0.5110Beat/MissBeat by +$0.0890One Year Ago EPS$0.80EPS Beat Rate6 of last 8 quartersPerrigo Revenue ResultsActual Revenue$988.60 millionExpected Revenue$984.80 millionBeat/MissBeat by +$3.80 millionYoY Revenue Growth-5.20%Conference Call ResourcesConference Call AudioConference Call TranscriptSlide DeckPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Perrigo Q3 2026 Earnings Call TranscriptProvided by QuartrNovember 4, 2026ShareShareShare This ReportLink copied to clipboard.Key Takeaways Positive Sentiment: Sequential operating trends improved: Core sales declined 1.7% year over year, a narrower drop than in the first half, while core adjusted operating margin rose to 14.3% from 13.4% in Q2. Perrigo also gained 30 basis points of U.S. store-brand OTC share and 80 basis points across key European brands. Negative Sentiment: Retailer inventory caution and European softness weighed on results and outlook. Management said retailers built less cough-and-cold inventory than expected and European demand remained weak; it lowered its 2026 sales outlook, while noting seasonal replenishment could fall in Q4 or Q1. Negative Sentiment: Core adjusted operating margin fell 210 basis points year over year to 14.3%, and core adjusted EPS declined $0.06 to $0.61. Lower sales and unfavorable mix hurt results; a 3.5% adjusted tax rate, including a year-to-date catch-up, added about $0.10 to quarterly core EPS. Positive Sentiment: The infant formula divestiture is expected to simplify the business, improve its margin profile, and reduce future capital needs. Perrigo expects to use proceeds in line with its capital priorities, including debt reduction, while continuing its review of oral care; its cost program delivered $42 million of savings year to date. AI Generated. May Contain Errors.Conference Call Audio Live Call not available Earnings Conference CallPerrigo Q3 202600:00 / 00:00Speed:1x1.25x1.5x2xTranscript SectionsPresentationParticipantsPresentationSkip to Participants Operator00:00:00Good morning, ladies and gentlemen, and welcome to the Perrigo third quarter 2026 financial results conference call. At this time, our lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Wednesday, November 4th, 2026. I would now like to turn the conference over to Eric Jacobson, Vice President, Global Investor Relations. Please go ahead, sir. Eric JacobsonVP of Global Investor Relations at Perrigo00:00:31Good morning and good afternoon, everyone. Welcome to Perrigo's third quarter 2026 earnings conference call. A copy of the release we issued today and the accompanying presentation are available within the Investors section of the perrigo.com website. Joining today's call are Perrigo's Interim President and CEO, Albert Manzone, and CFO, Eduardo Bezerra. As a reminder, we recently announced an agreement to divest our infant formula business. Beginning with the fourth quarter and full year 2026 reporting, the infant formula business will be reported as discontinued operations. Accordingly, the company's all-in outlook no longer includes infant formula. The company's core outlook continues to exclude infant formula and previously announced divestitures. During this presentation, participants will make certain forward-looking statements. Please refer to the slides for information regarding these statements, which are subject to important risks and uncertainties. We will reference adjusted financial measures that are non-GAAP in nature. Eric JacobsonVP of Global Investor Relations at Perrigo00:01:44See the appendix to the earnings presentation for additional details and reconciliations of all non-GAAP to GAAP financial measures presented. Moving to the agenda. Albert will begin with his perspective on Perrigo and the priorities he has identified. He will then discuss our third quarter performance, progress against the Three-S plan, and the commercial opportunities he sees to drive stronger, more consistent growth. Eduardo will then provide a financial review and discuss our 2026 outlook. With that, I'll turn it over to Albert. Albert ManzoneInterim President and CEO at Perrigo00:02:23Thanks, Eric. Good morning, good afternoon, and thank you for joining today's call. Over my first five months at Perrigo, I have spent a significant amount of time listening to our customers, our consumers, and our people, digging into the business and our capabilities, and developing a deeper understanding of what we do well and where we can be better. And I have been increasingly impressed. We have leading store brand products, strong brands, attractive positions across our categories, and a talented organization that knows the consumer self-care business exceptionally well. I want to thank our teams across Perrigo for their hard work, commitment, and the way they have welcomed me. At the same time, it has become clear why those strengths have not translated consistently into the results we should be delivering. Over time, Perrigo has become too complex. Albert ManzoneInterim President and CEO at Perrigo00:03:35The business has not been integrated to the degree it needs to be, and that complexity has made it harder for our teams to execute with the necessary speed and focus. We are taking decisive action to simplify and strengthen Perrigo, and that process is a major focus for me. That means being extremely deliberate about where we invest, the businesses and geographies where we play, and how we organize ourselves. We want our talented teams focused on the areas where Perrigo has the greatest right to win and where we see the most attractive risk-adjusted returns. This work is underway, and you will hear throughout today's call how we are sharpening our focus, simplifying the business, and positioning Perrigo to deliver more consistently over time. Looking at our key takeaways from the quarter. First, our Three-S plan is working. Albert ManzoneInterim President and CEO at Perrigo00:04:42There is more to do, but operating performance improved sequentially, and we are making progress in the areas we control. The sale of infant formula is an important step. It simplifies our portfolio and operations, improves our margin profile, reduces expected future CapEx, and allows us to focus our people and resources where we have the greatest right to win. Competitively, we gained share again in U.S. store brand OTC and across our key European brands. Category trends also continue to improve sequentially, even as the consumer environment remain challenging in certain areas. Finally, we have updated our 2026 outlook to reflect the infant formula divestment, more measured retailer inventory positioning ahead of the cough and cold season, and continued softness in Europe. While cough and cold incidence trends have shown early signs of improvements, retailers have taken a more measured approach to inventory. Albert ManzoneInterim President and CEO at Perrigo00:05:56Eduardo will take you through the details later in the call, including the key drivers underlying our expectation for the balance of the year. Turning briefly to our third quarter financial results. As you can see, our results continue to reflect some of the ongoing challenges we have discussed, including retailer inventory positioning and lower contract volumes. The key takeaway for me is straightforward. The areas we control are improving, even as external headwinds continue to weigh on the reported results. You can see that more clearly in the sequential trends. Our operating performance has improved each quarter this year. The year-over-year decline in core net sales has moderated from 8.3% in the first quarter to 3.1% in the second quarter to 1.7% in the third quarter. At the same time, core adjusted operating margin continued to trend upward, increasing from 12.8% to 13.4% to 14.3%. That is meaningful progress. Albert ManzoneInterim President and CEO at Perrigo00:07:10Category trends are improving, and the actions we are taking through our Three-S plan are having an impact. Our job now is to build on it, continue simplifying Perrigo, and translate that progress into more consistent results. In addition to the sequential improvement in our operating performance, we are seeing the category environment improve as well. As you can see, consumption trends have strengthened from the beginning of the year in both the U.S. and Europe. In the U.S., category volume returned to modest growth in the third quarter, while in Europe, consumer trends remain soft, but the rate of decline continued to improve sequentially, and so is our execution. Turning now to the details of our recent progress. Under stabilize, operations are becoming more consistent, and service is improving, which is strengthening our relationships and increasing collaboration with our retail customers. Albert ManzoneInterim President and CEO at Perrigo00:08:18Under streamline, we are making clear choices about where Perrigo should compete. We have sold Dermacosmetics and announced the divestment of infant formula while continuing the strategic review of oral care. We are taking cost out. Our Operational Enhancement Program has generated $42 million of savings year-to-date and remains on track to deliver approximately $60 million-$80 million in 2026. Under strengthen, we are putting more investment behind innovation, demand generation, and the parts of the portfolio where we see the greatest opportunity. We are seeing the results in our share performance in U.S. store brand OTC and across our key European brands. As we simplify Perrigo, we can enhance our focus on driving growth. These are three areas where I see clear opportunities. First, innovation. Albert ManzoneInterim President and CEO at Perrigo00:09:25We are directing innovation resources on categories where we have a right to win and where differentiated products can create meaningful value for consumer and customers. Second, distribution. Store brand is a core Perrigo strength, and we have opportunities to put more of our products in front of more consumers. That includes e-commerce, where our market share is already higher than in the total market. I will come back to that shortly. Third, demand generation. We are investing behind the brands, products, and customer programs where we believe we can generate attractive returns. That means stronger customer partnerships and more effective consumer engagement. The objective is simple: gain share and outgrow our categories. Let me bring some of those growth building blocks to life with a few examples. In store brands, we continue to find new ways to support consumers and create value for our retail partners. Albert ManzoneInterim President and CEO at Perrigo00:10:37Our GLP-1 activation is a good example, where we are positioning our digestive health portfolio to support consumers along their GLP-1 journey while deepening our strategic relationship with customers. Importantly, initiatives like this one shift more of our business into faster-growing parts of the category. At the same time, our investments behind key brands are translating into strong growth and share performance. Compeed, Opill, ellaOne, Jungle Formula, all deliver growth and gain share, demonstrating the opportunity we have when we put focused investment behind differentiated brands. These examples demonstrate the strengths of both sides of Perrigo. We have a differentiated store brand portfolio and brands with meaningful growth opportunities. As I mentioned earlier, e-commerce is a particularly attractive opportunity for Perrigo. The channel is growing faster than the broader category, and our share in e-commerce is higher than our share of the total market. That matters. Albert ManzoneInterim President and CEO at Perrigo00:11:52As more consumer purchasing moves online, we should benefit to a greater extent. We are seeing it already. U.S. e-commerce total category volume is up nearly 15% year-to-date, and e-commerce now represents 22% of our U.S. volume, up from approximately 13% in 2022. We have a strong position in a growing channel. Our job is to build on it. The clearest evidence that the Three-S plan is working is our share performance. In U.S. store brand OTC, volume grew 2% in the quarter, and we gained 30 basis points of share. In Europe, value sales in our key brands grew 6.5%, well ahead of their categories, and gained 80 basis points of share. Those are important proof points. We have more opportunity in front of us, but where we are investing and executing well, we are winning. Let me close with where I am focused. Albert ManzoneInterim President and CEO at Perrigo00:13:00We need to build on the share momentum we're seeing and continue expanding access to high-quality, affordable self-care products. We need to keep simplifying Perrigo. The sale of infant formula is an important step, and there is more to do. We need to strengthen the balance sheet and create greater financial flexibility. To ensure our capital allocation framework remains aligned with our strategy and market opportunities, we regularly review the most effective uses of capital across growth investments, debt reduction, and shareholder returns, including assessing the dividend on a quarterly basis. We need to deliver. We have work ahead of us, but I believe we have the portfolio, the capabilities, and the people to do it. With that, I will turn it over to Eduardo to walk through the financial results in more detail. Eduardo BezerraCFO at Perrigo00:13:59Thank you, Albert. I appreciate everyone joining us today. Other than for references to net sales, my comments will focus on adjusted non-GAAP results unless otherwise noted. Turning to our Q3 results, starting with the top line. Core net sales declined 1.7% year-over-year, while core organic net sales declined 1.1%. Importantly, as Albert highlighted, this marks another quarter of sequential improvement, reflecting both continued execution of our Three-S plan and improving category trends across several of our key markets. Third quarter results continued to reflect a softer consumption environment. The softness, which was particularly evident in our European business, contributed to more measured retailer inventory positioning ahead of the cough and cold season within the self-care segment. These factors represented approximately a 2 percentage point headwind to growth. Lower contract manufacturing volumes created an additional headwind of roughly 1 percentage point. Eduardo BezerraCFO at Perrigo00:15:14Encouragingly, our growth-building initiatives continued to gain traction, offsetting a meaningful portion of those pressures. Innovation and market share growth contributed approximately 1.5 percentage points of growth during the quarter. While the external environment remained challenging, these actions reinforce our confidence in the underlying trajectory of the business. Within self-care, net sales decreased 3.2%. The decline was concentrated in upper respiratory and pain and sleep categories, where softer consumption contributed to more measured retailer inventory positioning. Lower contract manufacturing volumes also weighed on results. These factors were partially offset by growth in healthy lifestyle, supported by continued share gains in store brand nicotine replacement and in digestive health, where store brand laxative volumes increased. Specialty care net sales decreased 4.6%. Women's health continued to perform well, led by share gains and solid momentum in ellaOne, along with continued growth from Opill. Eduardo BezerraCFO at Perrigo00:16:30Within skin health, Compeed and Jungle Formula delivered strong in-season performance, but that growth was more than offset by lower store brand and contract manufactured minoxidil sales and lower Mederma sales. On an all-in basis, net sales were $989 million, down 5.2%. In addition to the core drivers I just discussed, all-in results also reflected the impact of divestitures and lower infant formula sales, which together represented a 3.2% headwind. Infant formula net sales decreased 9.6% as growth in store brand formula was more than offset by lower contract volumes, including the timing of certain shipments that were recorded in the second quarter. Currency translation was a half percentage point headwind. Now to adjusted operating income. Self-care adjusted operating income decreased $25 million, or 19.4%. Eduardo BezerraCFO at Perrigo00:17:37The decline was driven primarily by lower sales, particularly in our higher-margin European business, which resulted in unfavorable mix along with increased advertising and promotional investment. Benefits from the Operational Enhancement Program partially offset those pressures. Specialty care adjusted operating income decreased $10 million, or 24.2%, reflecting unfavorable mix in skin health and higher advertising and promotion investment across the segment. These investments continue to support the consumer programs and innovation activity Albert discussed, while Operational Enhancement Program savings provided a partial offset. Infant formula adjusted operating income decreased by approximately $15 million and was slightly negative in the quarter. Lower sales and gross profit flow-through, including planned under absorption, were partially offset by lower operating expenses. Within all other, adjusted operating income increased approximately $4 million, or 18.4%. Eduardo BezerraCFO at Perrigo00:18:51Results benefited from the recognition of our recovery of a portion of previously paid tariffs, along with improved productivity and lower operating expenses in oral care. Those benefits more than offset the impact of divestitures. Corporate expenses improved modestly year-over-year, reflecting continued cost discipline and benefits from the Operational Enhancement Program, partially offset by the normalization of variable employee compensation. Turning to margins. The drivers were consistent with the segment results I just revealed. Core adjusted gross margin declined 140 basis points to 37.9%, driven by lower net sales volumes and unfavorable mix from lower sales in our higher-margin European business, partially offset by the benefit of tariffs and the contribution from continued market share gains. Core adjusted operating margin decreased 210 basis points to 14.3%. Eduardo BezerraCFO at Perrigo00:19:58In addition to the gross margin pressure, operating expenses increased primarily due to higher advertising promotion investment and the normalization of variable employee compensation. That increase was partially offset by Operational Enhancement Program benefits of $19 million. All-in adjusted gross margin declined 370 basis points to 36.3%, reflecting the core drivers as well as the impact of divestitures and lower infant formula gross margin, including planned under absorption. All-in adjusted operating margin decreased 360 basis points to 13.1%, reflecting those same items and the impact of infant formula and divestitures. Third quarter core adjusted earnings per share was $0.61, down $0.06 from the prior year. Lower sales and operating income were partially offset by a lower adjusted effective tax rate. Eduardo BezerraCFO at Perrigo00:21:06Changes in the jurisdictional mix of earnings reduced the adjusted effective tax rate to 3.5% and benefited core adjusted earnings per share by approximately $0.10 in the quarter. The Q3 tax rate benefit included a year-to-date catch-up to reflect the updated jurisdictional mix of earnings. All-in adjusted diluted earnings per share was $0.60, down $0.20 from the prior year. In addition to the core drivers, all-in earnings per share reflected the impact of divestitures and infant formula, including approximately $0.12 of unfavorable earnings per share impact from planned under absorption within infant formula. Turning to cash flow. Third quarter 2026 cash from operating activities was $96 million, in line with our expectations. Capital expenditures totaled $18 million, and we returned $40 million to shareholders through dividends. Turning to the balance sheet. Eduardo BezerraCFO at Perrigo00:22:14Cash and cash equivalents were $437 million, and total debt was $3.3 billion. Subsequent to quarter end, we announced an agreement to divest the infant formula business. Net proceeds are expected to be deployed in line with our capital allocation priorities, including sustainable business growth, reducing total debt and net leverage, and maintaining a disciplined and balanced capital allocation framework. Turning to our outlook. As Eric mentioned at the beginning, going forward, the infant formula business will be presented as discontinued operations. Starting with core, we now expect reported net sales to decline 2.5%-3.6%, with organic net sales declining 2.7%-3.8%. We expect adjusted gross margin of 37.5%-38.5%, adjusted operating margin of 14%-15%, and adjusted diluted earnings per share of $2.15-$2.35. Eduardo BezerraCFO at Perrigo00:23:27For all-in, which now excludes infant formula but includes other divestitures, we expect reported net sales to decline 4.6%-5.7%. With infant formula now accounted for in discontinued operations, we expect a benefit to adjusted gross margin and operating margins compared to our previous all-in outlook. We now expect adjusted gross margin of 37.8%-38.8% and adjusted operating margin of 14.3%-15.3%. All-in adjusted diluted earnings per share expected to be between $2.25 and $2.45. For both core and all-in, we assume net interest expense of approximately $162 million and adjusted effective tax rate of approximately 14% for the year, and approximately 140 million diluted shares outstanding. We also expect year-end net leverage of approximately four times adjusted EBITDA. Eduardo BezerraCFO at Perrigo00:24:43All-in cash from operating activities as a percentage of adjusted net income is expected to be in the low to mid-60% range. The change to our outlook reflects two primary factors: more measured retailer inventory position heading into the cough and cold season, and continued softness in the European consumer environment. While cough and cold incidence trends have been tracking favorably early in the fourth quarter, retailers have taken a more conservative approach to inventory levels following two consecutive seasons of softer category volumes. As a result, we saw lower retailer inventory build in the third quarter than previously assumed, which impacts our sales outlook despite encouraging early illness and tracked channel consumption trends. In Europe, the consumer environment remains challenging and is tracking below our prior expectations. As a result, we believe it's prudent to take a more measured view for the balance of the year. Eduardo BezerraCFO at Perrigo00:25:49Our operating assumptions continue to incorporate benefits from market share gains, innovation, distribution expansion, demand generation activities, and productivity benefits from our Operational Enhancement Program. As we moved into the fourth quarter, we remain focused on converting our market share gains and commercial investments into sales, managing costs with discipline, and executing against our updated outlook. While we remain mindful of the uncertain consumer environment and potential for variability in seasonal incident levels, we believe the actions we're taking position Perrigo to exit 2026 as a simpler and more focused consumer self-care company. Before I turn the call to Eric, I want to thank all our colleagues across Perrigo for their continued focus, commitment, and diligent execution. Eric. Eric JacobsonVP of Global Investor Relations at Perrigo00:26:46Thank you, Eduardo. Operator, we are now ready for questions. Operator00:26:51Thank you, Mr. Jacobson. Ladies and gentlemen, we now begin the question-and-answer session. If you would like to ask a question, please press star followed by the number one on your telephone keypad. If your question has been answered and you would like to withdraw from the queue, please press star followed by the number two. If you are using a speakerphone, please lift your hands before pressing any keys. One moment, please, while we compile the roster. Your first question comes from Susan Anderson with Canaccord Genuity. Please go ahead. Susan AndersonAnalyst at Canaccord Genuity00:27:20Hi. Good morning. Thanks for taking my questions, and congrats on the infant formula sale. I guess now with that infant formula sold, maybe just looking bigger picture, I guess, how are you thinking about the strategy of the business? Has anything changed there? Is oral care still planned to be sold, and where are you at with that business? Are there any other areas of the business that you think would make sense to divest? Then, if there is just any update to your strategy for the store brands and branded part of the business. Thanks. Albert ManzoneInterim President and CEO at Perrigo00:27:52Good morning, Susan. Thank you for the question. I hope you are well. Listen, we are, as you say, satisfied with the sale of infant formula. With regard to oral care, the process is ongoing, and at this point, those are the two assets that we are reviewing as a whole. What that means for us, as I said in my notes earlier, is really the ability to focus, simplify the company, and really focus on driving growth, improving our margins, and doing a disciplined allocation of capital. This is, I think, from a strategic standpoint, a big opportunity that we do have. I think over the coming quarters, you are going to see more of that. We are very satisfied with the market share gains that we are demonstrating and showing progress in the areas we control with regard to this quarter. Albert ManzoneInterim President and CEO at Perrigo00:28:58We continue to look at continuing to do better going forward. Strategically, there are areas that I think are very promising when you look at our sales performance, innovation, and focusing on innovation on where we get the best value for our brands, capturing the e-commerce opportunities. As you have seen in the presentation, we have a higher market share in a category that is growing and also already representing 20% of our sales in the U.S. I think we're going to double down on that focus with the organization going forward. Susan AndersonAnalyst at Canaccord Genuity00:29:44Okay, great. Then maybe if I could just follow-up on the market share gains in the quarter. I guess maybe if you could talk more specifically about the categories where you're gaining share, both in store brands and then separately in your branded business. I guess, are you seeing the gains across the entire portfolio, or are there certain categories or brands where you're seeing the most market share gains? Thanks. Albert ManzoneInterim President and CEO at Perrigo00:30:08Yeah, great question. If you look at the U.S., we're doing well across most of the categories. This is, as you know, we're putting a lot of focus on rebuilding the business with the retailer. I talked to you at the last quarter, and this is part of sequential improvements about improving our service levels to those retailers, and with our key retailers who are 95 and above. We are continuing to do that. That allows us, as I said earlier last quarter, to sit down with those retailers and co-innovate with them, and also creating demand generation. We do have a number of tests going on in terms of generating demand generations for the store brands. That growth is consistent across, a little bit less on the oral electrolytes and skin health, mostly there due to one brand, minoxidil. Albert ManzoneInterim President and CEO at Perrigo00:31:08On all the others, you are seeing a progress. You are also seeing new opportunities, as, for example, we're bundling together digestive health for GLP-1 consumers, and we're rolling this out across a number of retailers as we speak. You know that we're gaining share within the store brands, but we also do see opportunities to gain share as the total store brand business on behalf of the retailers. This is something that they are interested to develop. This is something that I think the consumer is looking at. As I was telling you earlier, when you look at e-commerce and when you look at the agents, you can imagine easily that an AI agent is at some point going to recommend a brand that costs a lot less that has exactly the same FDA ingredients. Albert ManzoneInterim President and CEO at Perrigo00:32:05Those are opportunities that we carry forward that allow us to gain share. What you see in Europe is also share gains across all our significant, I would say, bigger brands. There, we are doing well. We need to make sure that we support more broadly some of the other brands, and we have sometimes in Europe a leaky bucket. This is an area of focus of mine, going into some of those brands which have potential with a little bit of support. That market share trends and overall position in Europe can continue to grow as we go forward. Susan AndersonAnalyst at Canaccord Genuity00:32:48Okay, great. Thanks for all the details there. Good luck the rest of the year. Albert ManzoneInterim President and CEO at Perrigo00:32:54Thank you. Operator00:32:56Thank you, Susan. Your next question comes from Chris Schott with JPMorgan. Please go ahead. Analyst at JPMorgan00:33:02Hi, this is Ethan on for Chris Schott. Thanks for taking our questions and congrats on the quarter. Just starting off, as we look maybe to 2027 and given the number of moving pieces in the business, how are you thinking about the key pushes and pulls? As part of that, can you quantify the benefit from the tariff reversal this quarter? Albert ManzoneInterim President and CEO at Perrigo00:33:23Yes. Good morning, Ethan. As you may guess, I am going to be talking less about 2027, and you will hear more about this in the next quarter. Let me maybe give you some of the positives as I look at 2027 and some of the watch-outs. I think on the positive side, you are going to see an improving of the under absorption on OTC, which as you remember, was negatively impacted the first half of 2026. You are going to continue to see Operational Enhancement Programs, which we are working on and feel comfortable about. We are continuing, you are going to see the margin improvement from the divestment of infant formula in 2027. The watch-out, and I shouldn't surprise you there, is that obviously the Dermacosmetics divestiture has taken place. Albert ManzoneInterim President and CEO at Perrigo00:34:22You will see a normalization of the tax rate, which, as you know, has been positive this year due to the jurisdictions where it took place. The one-time benefits on the tariffs is going to go away. We continue to see, of course, inflationary pressure, and those will be coming still in 2027. Together with that, we are going to make sure, as I have said in my opening statement, that we invest where it does matter behind our brands, behind innovation, demand generation. The key for us is going to grow the business next year, and that's what we intend to do. Eduardo BezerraCFO at Perrigo00:35:05Ethan, regarding your question on tariffs, for Q3, the benefit of tariffs was about $4.5 million. Okay? Analyst at JPMorgan00:35:15Perfect. That's super helpful. One other question from me would just be following the impact or following the infant formula divestiture, how are you thinking about the company's broader cash flow going forward, and maybe in particular, the magnitude of impact on CapEx that this divestiture will have? Thank you. Albert ManzoneInterim President and CEO at Perrigo00:35:34Yeah, Ethan. Eduardo, you want to take this one? Eduardo BezerraCFO at Perrigo00:35:36Yeah. Ethan, I think there are a couple of things there. First, as we mentioned when we set guidance this year, infant formula was consuming cash because of the performance of this year. I think with this divestment, we remove that uncertainty. Also, as you remember, a couple of years ago, we mentioned that we would make significant investment to optimize our overall network and footprint. At that time, we announced potentially $240 million. We did a small portion of those investments over the past two years to make sure we kept the operations ongoing and finalized some of the previous committed investments. It's going to be a significant reduction on our capital requirements going forward. The positive on that side is we're going to be able to shift the focus to our core. Eduardo BezerraCFO at Perrigo00:36:37OTC business, right? As we see opportunities on investing in different areas that we believe are going to bring us a better potential return and more aligned with our ongoing core strategy. Analyst at JPMorgan00:36:53Great. Thank you guys so much for the questions, and congrats again on the quarter. Albert ManzoneInterim President and CEO at Perrigo00:36:58Thank you, Ethan. Operator00:37:00Thank you, Ethan. Your next question comes from Daniel Biolsi with Hedgeye. Please go ahead. Machado RodriguezAnalyst at Hedgeye00:37:07Hi, Machado Rodriguez on for Daniel. Thanks for taking the question. You highlighted more cautious inventory positioning ahead of cough and cold season. Just to clarify, are retailers actively reducing inventories again, or are they just simply not rebuilding ahead of the season? Albert ManzoneInterim President and CEO at Perrigo00:37:25Yes, thank you for the question. Good one. I would say that going Q3, we didn't see the retailer, as you said, it's the second piece of your assumption. They didn't load it for the season as they could have done or they did in the past. The season as start seems to be moving more into the year as climate change and so on and so forth. That's what you have seen. As a result, as far as we're concerned, we continue to see a season that should be better than last year, but maybe not as high as originally estimated. That being said, I think it's too early to tell because as we talk, the climate is getting colder, more people are getting sick. We saw some positive trends in October coming from the Southwest of the U.S. Albert ManzoneInterim President and CEO at Perrigo00:38:26In Europe, you start to have cough and cold season coming. We're ready for replenishments, no issues there. The question is really, is it going to impact the Q4? Is it going to impact the Q1? As again, this season seems to be shifting in terms of the calendar. Machado RodriguezAnalyst at Hedgeye00:38:48Okay, great. Thank you. Just to follow-up on that, do you see an opportunity for restocking to be a tailwind for sales, or do you think retailers are going to maintain lower inventory levels going forward? Albert ManzoneInterim President and CEO at Perrigo00:39:01I think that if the season picks up, which is still to be determined, you are going to see replenishment. What again, I cannot tell you is whether that replenishment is going to hit more into Q4 or into Q1 of next year. Machado RodriguezAnalyst at Hedgeye00:39:19Okay, great. Thanks for the questions and congrats on the quarter. Albert ManzoneInterim President and CEO at Perrigo00:39:24Thank you. Operator00:39:26Thank you. There are no further questions at this time. I will turn it back to Mr. Manzone for some concluding remarks. Albert ManzoneInterim President and CEO at Perrigo00:39:36Thank you, Anas, and thank you all for joining and for your questions. Operator00:39:44Ladies and gentlemen, this concludes your- Albert ManzoneInterim President and CEO at Perrigo00:39:44Let me close with what No, no, I just wanted to add something, if you allow me, which is, I just wanted to give you some reflection about what I have come to see in this company over the past five months. Perrigo holds a position that is hard to replicate. We are the leader in U.S. store brands OTC. We own a portfolio of leading brands in Europe. Very few companies can serve consumer across brands, store brands, categories, and price points the way we do. That gives us the ability to capture demand as consumer preferences shift. We are gaining share on both sides of the Atlantic, and e-commerce is driving further improvement. Our share in e-commerce is already higher than our share in the total market, and as more purchasing moves online, we should benefit to a greater extent. Albert ManzoneInterim President and CEO at Perrigo00:40:38What has held this company back is not the assets, it is complexity. That is what we are taking out quarter-by-quarter. There is real work ahead to simplify Perrigo, execute with greater consistency, and optimize our capabilities and assets to drive stronger performance. We know what we have to do, we are doing it, and I am confident in where we are headed. Thank you all for your continued interest in Perrigo. Operator00:41:23Ladies and gentlemen, this concludes your conference call for today. We thank you for participating and ask that you please disconnect your lines. Have a great day.Read moreParticipantsExecutivesEric JacobsonVP of Global Investor RelationsAlbert ManzoneInterim President and CEOAnalystsEduardo BezerraCFO at PerrigoSusan AndersonAnalyst at Canaccord GenuityAnalyst at JPMorganMachado RodriguezAnalyst at HedgeyePowered by Earnings DocumentsSlide DeckPress Release(8-K)Quarterly report(10-Q) Perrigo Q3 2026 Earnings FAQ Did Perrigo beat earnings estimates for Q3 2026? Perrigo (NYSE:PRGO) reported earnings of $0.60 per share for Q3 2026, beating the consensus estimate of $0.5110. The report was announced on Wednesday, November 4, 2026. What was Perrigo's revenue for Q3 2026? Perrigo reported revenue of $988.60 million for Q3 2026, against a consensus estimate of $984.80 million. Where can I read Perrigo's Q3 2026 earnings call transcript? The full Perrigo Q3 2026 earnings conference call transcript is published on this page, including prepared remarks and the analyst Q&A session, along with the participants who spoke on the call. Perrigo Earnings HeadlinesPerrigo Earnings Call Shows Progress Amid PressureNovember 14, 2026 | tipranks.comPerrigo Company plc (NYSE:PRGO) Stock Now Rated "Reduce" by Wall Street AnalystsNovember 12, 2026 | americanbankingnews.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 22 at 1:00 AM | Base Camp Trading (Ad)Perrigo to Attend the Jefferies Miami Consumer ConferenceNovember 11, 2026 | prnewswire.comHow Investors May Respond To Perrigo (PRGO) Weak 2026 OutlookNovember 7, 2026 | finance.yahoo.comIs Perrigo (PRGO) Undervalued After Its 2026 Sales Guidance Cut?November 7, 2026 | finance.yahoo.comSee More Perrigo Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Perrigo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Perrigo and other key companies, straight to your email. Email Address About PerrigoPerrigo (NYSE:PRGO) is a global consumer healthcare company that develops, manufactures and markets over-the-counter medicines and other self-care products. Its offerings include treatments for allergies, coughs and colds, pain and digestive health, as well as skin care, oral care and infant nutrition products. The company supplies both its own consumer brands and store-brand products, which retailers sell under their own labels. Perrigo serves customers primarily in North America and Europe through retail and other healthcare channels. Perrigo traces its roots to a general store opened in Allegan, Michigan, in 1887, where it began supplying medicines. The company is now headquartered in Dublin, Ireland.View Perrigo ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20Keysight Technologies: The Tollbooth on the Technology SuperhighwayGrowing Pains Versus Growth: Is BJ’s Wholesale Club a Buying Opportunity?Bargain Hunting: Why Off-Price Retail Is WinningZscaler Got a Boost From Palo Alto, But Now It Has to Deliver.If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PresentationSkip to Participants Operator00:00:00Good morning, ladies and gentlemen, and welcome to the Perrigo third quarter 2026 financial results conference call. At this time, our lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Wednesday, November 4th, 2026. I would now like to turn the conference over to Eric Jacobson, Vice President, Global Investor Relations. Please go ahead, sir. Eric JacobsonVP of Global Investor Relations at Perrigo00:00:31Good morning and good afternoon, everyone. Welcome to Perrigo's third quarter 2026 earnings conference call. A copy of the release we issued today and the accompanying presentation are available within the Investors section of the perrigo.com website. Joining today's call are Perrigo's Interim President and CEO, Albert Manzone, and CFO, Eduardo Bezerra. As a reminder, we recently announced an agreement to divest our infant formula business. Beginning with the fourth quarter and full year 2026 reporting, the infant formula business will be reported as discontinued operations. Accordingly, the company's all-in outlook no longer includes infant formula. The company's core outlook continues to exclude infant formula and previously announced divestitures. During this presentation, participants will make certain forward-looking statements. Please refer to the slides for information regarding these statements, which are subject to important risks and uncertainties. We will reference adjusted financial measures that are non-GAAP in nature. Eric JacobsonVP of Global Investor Relations at Perrigo00:01:44See the appendix to the earnings presentation for additional details and reconciliations of all non-GAAP to GAAP financial measures presented. Moving to the agenda. Albert will begin with his perspective on Perrigo and the priorities he has identified. He will then discuss our third quarter performance, progress against the Three-S plan, and the commercial opportunities he sees to drive stronger, more consistent growth. Eduardo will then provide a financial review and discuss our 2026 outlook. With that, I'll turn it over to Albert. Albert ManzoneInterim President and CEO at Perrigo00:02:23Thanks, Eric. Good morning, good afternoon, and thank you for joining today's call. Over my first five months at Perrigo, I have spent a significant amount of time listening to our customers, our consumers, and our people, digging into the business and our capabilities, and developing a deeper understanding of what we do well and where we can be better. And I have been increasingly impressed. We have leading store brand products, strong brands, attractive positions across our categories, and a talented organization that knows the consumer self-care business exceptionally well. I want to thank our teams across Perrigo for their hard work, commitment, and the way they have welcomed me. At the same time, it has become clear why those strengths have not translated consistently into the results we should be delivering. Over time, Perrigo has become too complex. Albert ManzoneInterim President and CEO at Perrigo00:03:35The business has not been integrated to the degree it needs to be, and that complexity has made it harder for our teams to execute with the necessary speed and focus. We are taking decisive action to simplify and strengthen Perrigo, and that process is a major focus for me. That means being extremely deliberate about where we invest, the businesses and geographies where we play, and how we organize ourselves. We want our talented teams focused on the areas where Perrigo has the greatest right to win and where we see the most attractive risk-adjusted returns. This work is underway, and you will hear throughout today's call how we are sharpening our focus, simplifying the business, and positioning Perrigo to deliver more consistently over time. Looking at our key takeaways from the quarter. First, our Three-S plan is working. Albert ManzoneInterim President and CEO at Perrigo00:04:42There is more to do, but operating performance improved sequentially, and we are making progress in the areas we control. The sale of infant formula is an important step. It simplifies our portfolio and operations, improves our margin profile, reduces expected future CapEx, and allows us to focus our people and resources where we have the greatest right to win. Competitively, we gained share again in U.S. store brand OTC and across our key European brands. Category trends also continue to improve sequentially, even as the consumer environment remain challenging in certain areas. Finally, we have updated our 2026 outlook to reflect the infant formula divestment, more measured retailer inventory positioning ahead of the cough and cold season, and continued softness in Europe. While cough and cold incidence trends have shown early signs of improvements, retailers have taken a more measured approach to inventory. Albert ManzoneInterim President and CEO at Perrigo00:05:56Eduardo will take you through the details later in the call, including the key drivers underlying our expectation for the balance of the year. Turning briefly to our third quarter financial results. As you can see, our results continue to reflect some of the ongoing challenges we have discussed, including retailer inventory positioning and lower contract volumes. The key takeaway for me is straightforward. The areas we control are improving, even as external headwinds continue to weigh on the reported results. You can see that more clearly in the sequential trends. Our operating performance has improved each quarter this year. The year-over-year decline in core net sales has moderated from 8.3% in the first quarter to 3.1% in the second quarter to 1.7% in the third quarter. At the same time, core adjusted operating margin continued to trend upward, increasing from 12.8% to 13.4% to 14.3%. That is meaningful progress. Albert ManzoneInterim President and CEO at Perrigo00:07:10Category trends are improving, and the actions we are taking through our Three-S plan are having an impact. Our job now is to build on it, continue simplifying Perrigo, and translate that progress into more consistent results. In addition to the sequential improvement in our operating performance, we are seeing the category environment improve as well. As you can see, consumption trends have strengthened from the beginning of the year in both the U.S. and Europe. In the U.S., category volume returned to modest growth in the third quarter, while in Europe, consumer trends remain soft, but the rate of decline continued to improve sequentially, and so is our execution. Turning now to the details of our recent progress. Under stabilize, operations are becoming more consistent, and service is improving, which is strengthening our relationships and increasing collaboration with our retail customers. Albert ManzoneInterim President and CEO at Perrigo00:08:18Under streamline, we are making clear choices about where Perrigo should compete. We have sold Dermacosmetics and announced the divestment of infant formula while continuing the strategic review of oral care. We are taking cost out. Our Operational Enhancement Program has generated $42 million of savings year-to-date and remains on track to deliver approximately $60 million-$80 million in 2026. Under strengthen, we are putting more investment behind innovation, demand generation, and the parts of the portfolio where we see the greatest opportunity. We are seeing the results in our share performance in U.S. store brand OTC and across our key European brands. As we simplify Perrigo, we can enhance our focus on driving growth. These are three areas where I see clear opportunities. First, innovation. Albert ManzoneInterim President and CEO at Perrigo00:09:25We are directing innovation resources on categories where we have a right to win and where differentiated products can create meaningful value for consumer and customers. Second, distribution. Store brand is a core Perrigo strength, and we have opportunities to put more of our products in front of more consumers. That includes e-commerce, where our market share is already higher than in the total market. I will come back to that shortly. Third, demand generation. We are investing behind the brands, products, and customer programs where we believe we can generate attractive returns. That means stronger customer partnerships and more effective consumer engagement. The objective is simple: gain share and outgrow our categories. Let me bring some of those growth building blocks to life with a few examples. In store brands, we continue to find new ways to support consumers and create value for our retail partners. Albert ManzoneInterim President and CEO at Perrigo00:10:37Our GLP-1 activation is a good example, where we are positioning our digestive health portfolio to support consumers along their GLP-1 journey while deepening our strategic relationship with customers. Importantly, initiatives like this one shift more of our business into faster-growing parts of the category. At the same time, our investments behind key brands are translating into strong growth and share performance. Compeed, Opill, ellaOne, Jungle Formula, all deliver growth and gain share, demonstrating the opportunity we have when we put focused investment behind differentiated brands. These examples demonstrate the strengths of both sides of Perrigo. We have a differentiated store brand portfolio and brands with meaningful growth opportunities. As I mentioned earlier, e-commerce is a particularly attractive opportunity for Perrigo. The channel is growing faster than the broader category, and our share in e-commerce is higher than our share of the total market. That matters. Albert ManzoneInterim President and CEO at Perrigo00:11:52As more consumer purchasing moves online, we should benefit to a greater extent. We are seeing it already. U.S. e-commerce total category volume is up nearly 15% year-to-date, and e-commerce now represents 22% of our U.S. volume, up from approximately 13% in 2022. We have a strong position in a growing channel. Our job is to build on it. The clearest evidence that the Three-S plan is working is our share performance. In U.S. store brand OTC, volume grew 2% in the quarter, and we gained 30 basis points of share. In Europe, value sales in our key brands grew 6.5%, well ahead of their categories, and gained 80 basis points of share. Those are important proof points. We have more opportunity in front of us, but where we are investing and executing well, we are winning. Let me close with where I am focused. Albert ManzoneInterim President and CEO at Perrigo00:13:00We need to build on the share momentum we're seeing and continue expanding access to high-quality, affordable self-care products. We need to keep simplifying Perrigo. The sale of infant formula is an important step, and there is more to do. We need to strengthen the balance sheet and create greater financial flexibility. To ensure our capital allocation framework remains aligned with our strategy and market opportunities, we regularly review the most effective uses of capital across growth investments, debt reduction, and shareholder returns, including assessing the dividend on a quarterly basis. We need to deliver. We have work ahead of us, but I believe we have the portfolio, the capabilities, and the people to do it. With that, I will turn it over to Eduardo to walk through the financial results in more detail. Eduardo BezerraCFO at Perrigo00:13:59Thank you, Albert. I appreciate everyone joining us today. Other than for references to net sales, my comments will focus on adjusted non-GAAP results unless otherwise noted. Turning to our Q3 results, starting with the top line. Core net sales declined 1.7% year-over-year, while core organic net sales declined 1.1%. Importantly, as Albert highlighted, this marks another quarter of sequential improvement, reflecting both continued execution of our Three-S plan and improving category trends across several of our key markets. Third quarter results continued to reflect a softer consumption environment. The softness, which was particularly evident in our European business, contributed to more measured retailer inventory positioning ahead of the cough and cold season within the self-care segment. These factors represented approximately a 2 percentage point headwind to growth. Lower contract manufacturing volumes created an additional headwind of roughly 1 percentage point. Eduardo BezerraCFO at Perrigo00:15:14Encouragingly, our growth-building initiatives continued to gain traction, offsetting a meaningful portion of those pressures. Innovation and market share growth contributed approximately 1.5 percentage points of growth during the quarter. While the external environment remained challenging, these actions reinforce our confidence in the underlying trajectory of the business. Within self-care, net sales decreased 3.2%. The decline was concentrated in upper respiratory and pain and sleep categories, where softer consumption contributed to more measured retailer inventory positioning. Lower contract manufacturing volumes also weighed on results. These factors were partially offset by growth in healthy lifestyle, supported by continued share gains in store brand nicotine replacement and in digestive health, where store brand laxative volumes increased. Specialty care net sales decreased 4.6%. Women's health continued to perform well, led by share gains and solid momentum in ellaOne, along with continued growth from Opill. Eduardo BezerraCFO at Perrigo00:16:30Within skin health, Compeed and Jungle Formula delivered strong in-season performance, but that growth was more than offset by lower store brand and contract manufactured minoxidil sales and lower Mederma sales. On an all-in basis, net sales were $989 million, down 5.2%. In addition to the core drivers I just discussed, all-in results also reflected the impact of divestitures and lower infant formula sales, which together represented a 3.2% headwind. Infant formula net sales decreased 9.6% as growth in store brand formula was more than offset by lower contract volumes, including the timing of certain shipments that were recorded in the second quarter. Currency translation was a half percentage point headwind. Now to adjusted operating income. Self-care adjusted operating income decreased $25 million, or 19.4%. Eduardo BezerraCFO at Perrigo00:17:37The decline was driven primarily by lower sales, particularly in our higher-margin European business, which resulted in unfavorable mix along with increased advertising and promotional investment. Benefits from the Operational Enhancement Program partially offset those pressures. Specialty care adjusted operating income decreased $10 million, or 24.2%, reflecting unfavorable mix in skin health and higher advertising and promotion investment across the segment. These investments continue to support the consumer programs and innovation activity Albert discussed, while Operational Enhancement Program savings provided a partial offset. Infant formula adjusted operating income decreased by approximately $15 million and was slightly negative in the quarter. Lower sales and gross profit flow-through, including planned under absorption, were partially offset by lower operating expenses. Within all other, adjusted operating income increased approximately $4 million, or 18.4%. Eduardo BezerraCFO at Perrigo00:18:51Results benefited from the recognition of our recovery of a portion of previously paid tariffs, along with improved productivity and lower operating expenses in oral care. Those benefits more than offset the impact of divestitures. Corporate expenses improved modestly year-over-year, reflecting continued cost discipline and benefits from the Operational Enhancement Program, partially offset by the normalization of variable employee compensation. Turning to margins. The drivers were consistent with the segment results I just revealed. Core adjusted gross margin declined 140 basis points to 37.9%, driven by lower net sales volumes and unfavorable mix from lower sales in our higher-margin European business, partially offset by the benefit of tariffs and the contribution from continued market share gains. Core adjusted operating margin decreased 210 basis points to 14.3%. Eduardo BezerraCFO at Perrigo00:19:58In addition to the gross margin pressure, operating expenses increased primarily due to higher advertising promotion investment and the normalization of variable employee compensation. That increase was partially offset by Operational Enhancement Program benefits of $19 million. All-in adjusted gross margin declined 370 basis points to 36.3%, reflecting the core drivers as well as the impact of divestitures and lower infant formula gross margin, including planned under absorption. All-in adjusted operating margin decreased 360 basis points to 13.1%, reflecting those same items and the impact of infant formula and divestitures. Third quarter core adjusted earnings per share was $0.61, down $0.06 from the prior year. Lower sales and operating income were partially offset by a lower adjusted effective tax rate. Eduardo BezerraCFO at Perrigo00:21:06Changes in the jurisdictional mix of earnings reduced the adjusted effective tax rate to 3.5% and benefited core adjusted earnings per share by approximately $0.10 in the quarter. The Q3 tax rate benefit included a year-to-date catch-up to reflect the updated jurisdictional mix of earnings. All-in adjusted diluted earnings per share was $0.60, down $0.20 from the prior year. In addition to the core drivers, all-in earnings per share reflected the impact of divestitures and infant formula, including approximately $0.12 of unfavorable earnings per share impact from planned under absorption within infant formula. Turning to cash flow. Third quarter 2026 cash from operating activities was $96 million, in line with our expectations. Capital expenditures totaled $18 million, and we returned $40 million to shareholders through dividends. Turning to the balance sheet. Eduardo BezerraCFO at Perrigo00:22:14Cash and cash equivalents were $437 million, and total debt was $3.3 billion. Subsequent to quarter end, we announced an agreement to divest the infant formula business. Net proceeds are expected to be deployed in line with our capital allocation priorities, including sustainable business growth, reducing total debt and net leverage, and maintaining a disciplined and balanced capital allocation framework. Turning to our outlook. As Eric mentioned at the beginning, going forward, the infant formula business will be presented as discontinued operations. Starting with core, we now expect reported net sales to decline 2.5%-3.6%, with organic net sales declining 2.7%-3.8%. We expect adjusted gross margin of 37.5%-38.5%, adjusted operating margin of 14%-15%, and adjusted diluted earnings per share of $2.15-$2.35. Eduardo BezerraCFO at Perrigo00:23:27For all-in, which now excludes infant formula but includes other divestitures, we expect reported net sales to decline 4.6%-5.7%. With infant formula now accounted for in discontinued operations, we expect a benefit to adjusted gross margin and operating margins compared to our previous all-in outlook. We now expect adjusted gross margin of 37.8%-38.8% and adjusted operating margin of 14.3%-15.3%. All-in adjusted diluted earnings per share expected to be between $2.25 and $2.45. For both core and all-in, we assume net interest expense of approximately $162 million and adjusted effective tax rate of approximately 14% for the year, and approximately 140 million diluted shares outstanding. We also expect year-end net leverage of approximately four times adjusted EBITDA. Eduardo BezerraCFO at Perrigo00:24:43All-in cash from operating activities as a percentage of adjusted net income is expected to be in the low to mid-60% range. The change to our outlook reflects two primary factors: more measured retailer inventory position heading into the cough and cold season, and continued softness in the European consumer environment. While cough and cold incidence trends have been tracking favorably early in the fourth quarter, retailers have taken a more conservative approach to inventory levels following two consecutive seasons of softer category volumes. As a result, we saw lower retailer inventory build in the third quarter than previously assumed, which impacts our sales outlook despite encouraging early illness and tracked channel consumption trends. In Europe, the consumer environment remains challenging and is tracking below our prior expectations. As a result, we believe it's prudent to take a more measured view for the balance of the year. Eduardo BezerraCFO at Perrigo00:25:49Our operating assumptions continue to incorporate benefits from market share gains, innovation, distribution expansion, demand generation activities, and productivity benefits from our Operational Enhancement Program. As we moved into the fourth quarter, we remain focused on converting our market share gains and commercial investments into sales, managing costs with discipline, and executing against our updated outlook. While we remain mindful of the uncertain consumer environment and potential for variability in seasonal incident levels, we believe the actions we're taking position Perrigo to exit 2026 as a simpler and more focused consumer self-care company. Before I turn the call to Eric, I want to thank all our colleagues across Perrigo for their continued focus, commitment, and diligent execution. Eric. Eric JacobsonVP of Global Investor Relations at Perrigo00:26:46Thank you, Eduardo. Operator, we are now ready for questions. Operator00:26:51Thank you, Mr. Jacobson. Ladies and gentlemen, we now begin the question-and-answer session. If you would like to ask a question, please press star followed by the number one on your telephone keypad. If your question has been answered and you would like to withdraw from the queue, please press star followed by the number two. If you are using a speakerphone, please lift your hands before pressing any keys. One moment, please, while we compile the roster. Your first question comes from Susan Anderson with Canaccord Genuity. Please go ahead. Susan AndersonAnalyst at Canaccord Genuity00:27:20Hi. Good morning. Thanks for taking my questions, and congrats on the infant formula sale. I guess now with that infant formula sold, maybe just looking bigger picture, I guess, how are you thinking about the strategy of the business? Has anything changed there? Is oral care still planned to be sold, and where are you at with that business? Are there any other areas of the business that you think would make sense to divest? Then, if there is just any update to your strategy for the store brands and branded part of the business. Thanks. Albert ManzoneInterim President and CEO at Perrigo00:27:52Good morning, Susan. Thank you for the question. I hope you are well. Listen, we are, as you say, satisfied with the sale of infant formula. With regard to oral care, the process is ongoing, and at this point, those are the two assets that we are reviewing as a whole. What that means for us, as I said in my notes earlier, is really the ability to focus, simplify the company, and really focus on driving growth, improving our margins, and doing a disciplined allocation of capital. This is, I think, from a strategic standpoint, a big opportunity that we do have. I think over the coming quarters, you are going to see more of that. We are very satisfied with the market share gains that we are demonstrating and showing progress in the areas we control with regard to this quarter. Albert ManzoneInterim President and CEO at Perrigo00:28:58We continue to look at continuing to do better going forward. Strategically, there are areas that I think are very promising when you look at our sales performance, innovation, and focusing on innovation on where we get the best value for our brands, capturing the e-commerce opportunities. As you have seen in the presentation, we have a higher market share in a category that is growing and also already representing 20% of our sales in the U.S. I think we're going to double down on that focus with the organization going forward. Susan AndersonAnalyst at Canaccord Genuity00:29:44Okay, great. Then maybe if I could just follow-up on the market share gains in the quarter. I guess maybe if you could talk more specifically about the categories where you're gaining share, both in store brands and then separately in your branded business. I guess, are you seeing the gains across the entire portfolio, or are there certain categories or brands where you're seeing the most market share gains? Thanks. Albert ManzoneInterim President and CEO at Perrigo00:30:08Yeah, great question. If you look at the U.S., we're doing well across most of the categories. This is, as you know, we're putting a lot of focus on rebuilding the business with the retailer. I talked to you at the last quarter, and this is part of sequential improvements about improving our service levels to those retailers, and with our key retailers who are 95 and above. We are continuing to do that. That allows us, as I said earlier last quarter, to sit down with those retailers and co-innovate with them, and also creating demand generation. We do have a number of tests going on in terms of generating demand generations for the store brands. That growth is consistent across, a little bit less on the oral electrolytes and skin health, mostly there due to one brand, minoxidil. Albert ManzoneInterim President and CEO at Perrigo00:31:08On all the others, you are seeing a progress. You are also seeing new opportunities, as, for example, we're bundling together digestive health for GLP-1 consumers, and we're rolling this out across a number of retailers as we speak. You know that we're gaining share within the store brands, but we also do see opportunities to gain share as the total store brand business on behalf of the retailers. This is something that they are interested to develop. This is something that I think the consumer is looking at. As I was telling you earlier, when you look at e-commerce and when you look at the agents, you can imagine easily that an AI agent is at some point going to recommend a brand that costs a lot less that has exactly the same FDA ingredients. Albert ManzoneInterim President and CEO at Perrigo00:32:05Those are opportunities that we carry forward that allow us to gain share. What you see in Europe is also share gains across all our significant, I would say, bigger brands. There, we are doing well. We need to make sure that we support more broadly some of the other brands, and we have sometimes in Europe a leaky bucket. This is an area of focus of mine, going into some of those brands which have potential with a little bit of support. That market share trends and overall position in Europe can continue to grow as we go forward. Susan AndersonAnalyst at Canaccord Genuity00:32:48Okay, great. Thanks for all the details there. Good luck the rest of the year. Albert ManzoneInterim President and CEO at Perrigo00:32:54Thank you. Operator00:32:56Thank you, Susan. Your next question comes from Chris Schott with JPMorgan. Please go ahead. Analyst at JPMorgan00:33:02Hi, this is Ethan on for Chris Schott. Thanks for taking our questions and congrats on the quarter. Just starting off, as we look maybe to 2027 and given the number of moving pieces in the business, how are you thinking about the key pushes and pulls? As part of that, can you quantify the benefit from the tariff reversal this quarter? Albert ManzoneInterim President and CEO at Perrigo00:33:23Yes. Good morning, Ethan. As you may guess, I am going to be talking less about 2027, and you will hear more about this in the next quarter. Let me maybe give you some of the positives as I look at 2027 and some of the watch-outs. I think on the positive side, you are going to see an improving of the under absorption on OTC, which as you remember, was negatively impacted the first half of 2026. You are going to continue to see Operational Enhancement Programs, which we are working on and feel comfortable about. We are continuing, you are going to see the margin improvement from the divestment of infant formula in 2027. The watch-out, and I shouldn't surprise you there, is that obviously the Dermacosmetics divestiture has taken place. Albert ManzoneInterim President and CEO at Perrigo00:34:22You will see a normalization of the tax rate, which, as you know, has been positive this year due to the jurisdictions where it took place. The one-time benefits on the tariffs is going to go away. We continue to see, of course, inflationary pressure, and those will be coming still in 2027. Together with that, we are going to make sure, as I have said in my opening statement, that we invest where it does matter behind our brands, behind innovation, demand generation. The key for us is going to grow the business next year, and that's what we intend to do. Eduardo BezerraCFO at Perrigo00:35:05Ethan, regarding your question on tariffs, for Q3, the benefit of tariffs was about $4.5 million. Okay? Analyst at JPMorgan00:35:15Perfect. That's super helpful. One other question from me would just be following the impact or following the infant formula divestiture, how are you thinking about the company's broader cash flow going forward, and maybe in particular, the magnitude of impact on CapEx that this divestiture will have? Thank you. Albert ManzoneInterim President and CEO at Perrigo00:35:34Yeah, Ethan. Eduardo, you want to take this one? Eduardo BezerraCFO at Perrigo00:35:36Yeah. Ethan, I think there are a couple of things there. First, as we mentioned when we set guidance this year, infant formula was consuming cash because of the performance of this year. I think with this divestment, we remove that uncertainty. Also, as you remember, a couple of years ago, we mentioned that we would make significant investment to optimize our overall network and footprint. At that time, we announced potentially $240 million. We did a small portion of those investments over the past two years to make sure we kept the operations ongoing and finalized some of the previous committed investments. It's going to be a significant reduction on our capital requirements going forward. The positive on that side is we're going to be able to shift the focus to our core. Eduardo BezerraCFO at Perrigo00:36:37OTC business, right? As we see opportunities on investing in different areas that we believe are going to bring us a better potential return and more aligned with our ongoing core strategy. Analyst at JPMorgan00:36:53Great. Thank you guys so much for the questions, and congrats again on the quarter. Albert ManzoneInterim President and CEO at Perrigo00:36:58Thank you, Ethan. Operator00:37:00Thank you, Ethan. Your next question comes from Daniel Biolsi with Hedgeye. Please go ahead. Machado RodriguezAnalyst at Hedgeye00:37:07Hi, Machado Rodriguez on for Daniel. Thanks for taking the question. You highlighted more cautious inventory positioning ahead of cough and cold season. Just to clarify, are retailers actively reducing inventories again, or are they just simply not rebuilding ahead of the season? Albert ManzoneInterim President and CEO at Perrigo00:37:25Yes, thank you for the question. Good one. I would say that going Q3, we didn't see the retailer, as you said, it's the second piece of your assumption. They didn't load it for the season as they could have done or they did in the past. The season as start seems to be moving more into the year as climate change and so on and so forth. That's what you have seen. As a result, as far as we're concerned, we continue to see a season that should be better than last year, but maybe not as high as originally estimated. That being said, I think it's too early to tell because as we talk, the climate is getting colder, more people are getting sick. We saw some positive trends in October coming from the Southwest of the U.S. Albert ManzoneInterim President and CEO at Perrigo00:38:26In Europe, you start to have cough and cold season coming. We're ready for replenishments, no issues there. The question is really, is it going to impact the Q4? Is it going to impact the Q1? As again, this season seems to be shifting in terms of the calendar. Machado RodriguezAnalyst at Hedgeye00:38:48Okay, great. Thank you. Just to follow-up on that, do you see an opportunity for restocking to be a tailwind for sales, or do you think retailers are going to maintain lower inventory levels going forward? Albert ManzoneInterim President and CEO at Perrigo00:39:01I think that if the season picks up, which is still to be determined, you are going to see replenishment. What again, I cannot tell you is whether that replenishment is going to hit more into Q4 or into Q1 of next year. Machado RodriguezAnalyst at Hedgeye00:39:19Okay, great. Thanks for the questions and congrats on the quarter. Albert ManzoneInterim President and CEO at Perrigo00:39:24Thank you. Operator00:39:26Thank you. There are no further questions at this time. I will turn it back to Mr. Manzone for some concluding remarks. Albert ManzoneInterim President and CEO at Perrigo00:39:36Thank you, Anas, and thank you all for joining and for your questions. Operator00:39:44Ladies and gentlemen, this concludes your- Albert ManzoneInterim President and CEO at Perrigo00:39:44Let me close with what No, no, I just wanted to add something, if you allow me, which is, I just wanted to give you some reflection about what I have come to see in this company over the past five months. Perrigo holds a position that is hard to replicate. We are the leader in U.S. store brands OTC. We own a portfolio of leading brands in Europe. Very few companies can serve consumer across brands, store brands, categories, and price points the way we do. That gives us the ability to capture demand as consumer preferences shift. We are gaining share on both sides of the Atlantic, and e-commerce is driving further improvement. Our share in e-commerce is already higher than our share in the total market, and as more purchasing moves online, we should benefit to a greater extent. Albert ManzoneInterim President and CEO at Perrigo00:40:38What has held this company back is not the assets, it is complexity. That is what we are taking out quarter-by-quarter. There is real work ahead to simplify Perrigo, execute with greater consistency, and optimize our capabilities and assets to drive stronger performance. We know what we have to do, we are doing it, and I am confident in where we are headed. Thank you all for your continued interest in Perrigo. Operator00:41:23Ladies and gentlemen, this concludes your conference call for today. We thank you for participating and ask that you please disconnect your lines. Have a great day.Read moreParticipantsExecutivesEric JacobsonVP of Global Investor RelationsAlbert ManzoneInterim President and CEOAnalystsEduardo BezerraCFO at PerrigoSusan AndersonAnalyst at Canaccord GenuityAnalyst at JPMorganMachado RodriguezAnalyst at HedgeyePowered by